{"anticipatedPostingDate":"2027-03","denomUnitsSelected":"Participants","description":"CRR was defined as the percentage of participants with a BOR of confirmed sCR/CR per IMWG response criteria as determined by investigator. sCR: i) CR; ii) normal serum FLC ratio and absence of clonal cells in BMB/BMA by immunohistochemistry or immunofluorescence (κ/λ ratio \\<=4:1 or \\>=1:2 for κ and λ participants, respectively, after counting \\>=100 plasma cells; iii) if the only measurable disease was by serum FLC levels, sCR was defined as normal serum FLC ratio of 0.26 to 1.65 plus absence of clonal cells in BMB/BMA b by immunohistochemistry or immunofluorescence (κ/λ ratio \\<=4:1 or \\>=1:2 for κ and λ participants, respectively, after counting \\>=100 plasma cells). CR: i) negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \\<5% plasma cells in BMA; ii) if the only measurable disease was by serum FLC levels, CR was defined as normal serum FLC ratio of 0.26 to 1.65 plus criteria (i).","reportingStatus":"NOT_POSTED","timeFrame":"From treatment initiation till study completion","title":"SSB: CRR as Per IMWG Criteria as Determined by Investigator- Phase 1b Dose Escalation","type":"SECONDARY"}